HTGM - HTG Molecular Diagnostics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.59
+0.28 (+6.50%)
At close: 4:00PM EDT

4.58 -0.01 (-0.22%)
After hours: 4:43PM EDT

Stock chart is not supported by your current browser
Previous Close4.31
Open4.60
Bid4.60 x 900
Ask4.64 x 800
Day's Range4.47 - 4.67
52 Week Range1.65 - 5.83
Volume649,627
Avg. Volume539,028
Market Cap130.456M
Beta0.94
PE Ratio (TTM)N/A
EPS (TTM)-0.86
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
Trade prices are not sourced from all markets
  • TheStreet.com20 days ago

    Indexes Hold Onto Week's Gains

    The indices didn't' do much but they definitely did fall apart. was up over 5% this week which has a significant impact on the indices. The indices are extended as are many stocks, so you have to wonder when we will see some pullbacks but the worst thing you can do Is to keep anticipating a top.

  • GlobeNewswire21 days ago

    HTG Molecular to Present a Corporate Overview at the H.C. Wainwright 20th Annual Global Investment Conference

    TUCSON, Ariz., Aug. 30, 2018-- HTG Molecular Diagnostics, Inc., a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive ...

  • GlobeNewswire23 days ago

    HTG Introduces the HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay, a Comprehensive Panel for miRNA Expression Analysis for use in Translational Medicine and Preclinical Studies

    HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the pre-launch introduction of the new HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay (WTA) with product availability for shipment expected in the fourth quarter of 2018. The HTG EdgeSeq Mouse miRNA WTA is designed for use with disease mouse models, including oncology, to identify and quantify the expression of a wide range of miRNAs in a variety of sample types, including formalin‑fixed paraffin-embedded (FFPE) tissue. “We are excited to expand the HTG EdgeSeq assay portfolio to include an assay specific for profiling mouse microRNAs for labs using mouse models in translational medicine discovery, preclinical and toxicology studies,” stated Mike Hrubiak, Senior Vice President of HTG’s Profiling Business Unit.

  • GlobeNewswirelast month

    HTG Molecular Announces 2nd Amendment to Second Statement of Work with QIAGEN Manchester Limited

    HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into a second amendment to the second statement of work (“SOW Two”) under its Master Assay Development, Commercialization and Manufacturing Agreement with Qiagen Manchester Limited (“QML”). This second amendment enables the use of the investigational use only (“IUO”) assay developed in the initial-phase of SOW Two in additional disease indications. “We are very pleased to continue to expand our agreement and to take the next logical step in our immuno-oncology collaboration with the Pharma Partner and QML through the use of the existing IUO assay into multiple additional disease indications,” said Byron Lawson, Senior Vice President, Pharma Partnerships.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of HTGM earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 HTG Molecular Diagnostics Inc Earnings Call

  • GlobeNewswirelast month

    HTG Molecular Appoints Michelle R. Griffin to its Board of Directors

    “We are pleased to welcome Michelle to our Board,” said TJ Johnson, Chief Executive Officer of HTG. “Michelle brings deep financial and accounting expertise, in addition to her extensive executive experience, making her insights invaluable as HTG continues its growth trajectory.

  • GlobeNewswirelast month

    HTG Molecular Diagnostics Fulfills First Orders for its Next-Generation Sequencing-Based HTG EdgeSeq Precision Immuno-Oncology Panel

    HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced it launched its HTG EdgeSeq Precision Immuno-Oncology Panel and has delivered its first orders to translational and clinical researchers working in the field of cancer immunology and/or cancer immunotherapy. This Research Use Only profiling panel provides a large, comprehensive set of genes involved in the host immune response to tumors. While progress has been made in immuno-therapies, much work still remains on biomarker development to better identify patients who will respond or not respond to these therapies, and we believe our panel, with its 1,392 genes will go a long way in helping reach that goal,” said Mike Hrubiak, Senior Vice President of HTG’s Profiling Business Unit.

  • GlobeNewswirelast month

    Detailed Research: Economic Perspectives on Neos Therapeutics, Federated National Holding, FutureFuel, Golden Entertainment, Intra-Cellular Therapies, and HTG Molecular Diagnostics — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Neos ...

  • GlobeNewswirelast month

    HTG Molecular Announces Amendment to Second Statement of Work with QIAGEN Manchester Limited

    HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into an amendment to the second statement of work (“SOW Two”) under its Master Assay Development, Commercialization and Manufacturing Agreement with Qiagen Manchester Limited (“QML”). SOW Two relates to a project for which HTG and QML are performing collaborative development services for what is expected to be a multi-stage project leading to the potential development and commercialization of an NGS-based companion diagnostic assay in support of one or more of the therapeutic development and commercialization programs of Bristol-Myers Squibb Company (“BMS”).

  • TheStreet.comlast month

    Two Small Caps On the Cusp of Being Discovered

    It is sloppy and slow out there with some computer algorithms jerking the indices around. There aren't any big earnings reports driving the action today and there is a mishmash of stocks moving around.

  • HTG Molecular Diagnostics, Inc. (HTGM) Reports Q2 Loss, Lags Revenue Estimates
    Zackslast month

    HTG Molecular Diagnostics, Inc. (HTGM) Reports Q2 Loss, Lags Revenue Estimates

    HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 26.32% and -7.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswirelast month

    HTG Molecular Diagnostics Reports Second Quarter 2018 Results

    Revenue increased 179% and 190%, respectively, compared to the three and six-month periods in the prior year. Call scheduled for today, August 7, at 4:30 pm ET. TUCSON, Ariz., Aug. 07, 2018-- HTG Molecular ...

  • ACCESSWIRElast month

    HTG Molecular Diagnostics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM ...

  • GlobeNewswire2 months ago

    HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

    HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with operations in Boston and Shanghai, today announced the completion of a master agreement where the companies have agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline. “We are honored to be working with Oncologie on biomarker development programs for their innovative pipeline of Immuno-oncology assets,” stated TJ Johnson HTG Chief Executive Officer.

  • GlobeNewswire2 months ago

    HTG Molecular Diagnostics to Present at Canaccord Genuity Growth Conference

    TUCSON, Ariz., Aug. 01, 2018-- HTG Molecular Diagnostics, Inc., a provider of instruments, reagents, and services for molecular profiling applications, today announced TJ Johnson, Chief Executive Officer ...

  • GlobeNewswire2 months ago

    HTG Molecular Diagnostics to Announce Second Quarter and Six Months Ended June 30, 2018 Financial Results and Host Conference Call on Tuesday, August 7

    TUCSON, Ariz., July 24, 2018-- HTG Molecular Diagnostics, Inc., a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial ...

  • Zosano Pharma’s Positive Non-Clinical Trial Results
    Market Realist2 months ago

    Zosano Pharma’s Positive Non-Clinical Trial Results

    Today, Zosano Pharma is trading at a stock price of $4.38, which represents ~5.92% growth from its closing price of $4.14 yesterday. $4.14 represented ~15% growth from the stock’s 52-week low of $3.61 on February 13. Zosano Pharma hit a 52-week high of $27.8 on July 18, 2017.

  • HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM) Shift From Loss To Profit
    Simply Wall St.3 months ago

    HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM) Shift From Loss To Profit

    HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM): HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The US$97.03mRead More...

  • ACCESSWIRE3 months ago

    Free Stock Performance Review on Agilent Technologies and Three Additional Medical Research Stocks

    Today, WallStEquities.com evaluates the following Medical Laboratories and Research stocks: Agilent Technologies Inc. (NYSE: A), Biocept Inc. (NASDAQ: BIOC), Co-Diagnostics Inc. (NASDAQ: CODX), and HTG Molecular Diagnostics Inc. (NASDAQ: HTGM). Companies in the medical laboratories market are independent, commercial enterprises that provide information to healthcare professionals about the severity, onset, and reason of patients' physical ailments.

  • Investopedia4 months ago

    Penny Stocks to Watch for June 2018

    Positive seasonality for small caps and penny stocks has ended. Legacy Reserves LP ( LGCY) soared nearly 84% in the first two weeks of the month, posting a 3-year high, while solar manufacturer Enphase Energy, Inc. ( ENPH) broke out of a 2-month basing pattern and gained 40%. Enphase Energy, Inc. ( ENPH) posted an-all time high at $17.97 in September 2014 and broke down in May 2015, entering a brutal decline that ended at an all-time low at 65-cents in the second quarter of 2017.

  • Does HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM) Latest Financial Perfomance Look Strong?
    Simply Wall St.4 months ago

    Does HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM) Latest Financial Perfomance Look Strong?

    Examining HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has metRead More...